Director Andrew Schwab Sells $1.6M of Camp4 Stock via 5AM Ventures
CAMP has more than doubled off its 52-week low of $1.41.
Summary
Camp4 director Andrew Schwab sold $1.6 million of stock on August 27, adding to a recent pattern of insider selling following the company's $50.1 million private placement.
Key Events · Ownership and Investor Activity · CAMP
-
Director Sells $1.6M in Open Market
Andrew Schwab sold 400,000 shares at $4.04 on August 27, 2026, for total proceeds of $1,616,000 via 5AM Ventures VI, L.P.
-
Follows Prior $879K Sale
This sale comes six days after Schwab disclosed a $879,719 sale on August 21, bringing his recent open-market selling to approximately $2.5 million.
-
Post-Sale Holdings
Schwab retains 2,033,270 shares indirectly through 5AM Ventures VI, plus additional holdings through 5AM Ventures VII and 5AM Opportunities II.
-
Insider Distribution Pattern
The sale continues a 90-day insider distribution signal of $847,291 net, now increased by this transaction, following Camp4's $50.1 million private placement and resale registration.
Analysis · CAMP · Life Sciences
Director Andrew Schwab sold 400,000 shares for $1.6 million at $4.04 on August 27 through 5AM Ventures VI, L.P. This follows a $879,719 sale disclosed just six days earlier, bringing his recent open-market selling to roughly $2.5 million. The sale represents about 0.65% of the company's market cap and continues a pattern of insider distribution at Camp4, which recently completed a $50.1 million private placement and registered 32.7 million shares for resale.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $3.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $248.5M. The 52-week trading range was $1.41 to $7.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.